NICE recommends Opdivo (nivolumab) to treat advanced melanoma- BMS
The National Institute for Health and Care Excellence (NICE) has given a positive recommendation in a final appraisal for Opdivo (nivolumab) from BMS. NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma. The independent Committee decided that a consultation on the draft recommendations was not needed for this appraisal, so the recommendations could go straight to a final appraisal determination (FAD). This happens when the Committee recommends a treatment in line with its licence.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.